compounded semaglutide louisville ky Kit Medical Weight Loss GLP-1 in
Description
Madrigal is requesting approval of resmetirom under the FDAs accelerated approval pathway
Insights from Leading Scientists Dr
Among patients with UC, those treated with GLP1RA had lower rates of corticosteroid use (39.9% vs 76.0%), emergency department visits (41.9% vs 52.7%), hospitalization (30.6% vs 55.8%), intestinal resection (17.8% vs 53.9%), and mortality (5.8% vs 10.9%)
More severe side effects are also possible, depending on several factors including age and preexisting conditions
A Cleveland Clinic study also showed GLP-1s reduced the risk of progression of breast, lung, liver, and colorectal cancers by up to 50%
Consult a licensed clinician for treatment decisions.
